Dr Reddys Lab launches Chlorthalidone Tablets in US

Dr. Reddy’s Laboratories has launched Chlorthalidone Tablets USP, 25 mg and 50 mg. The company's share, however, fell intraday. 

Chlorthalidone Tablets USP, 25 mg and 50 mg, has been approved by the United States Food and Drug Association (USFDA). It is a generic version of Hygroton (chlorthalidone) Tablets. Chlorthalidone is used to treat high blood pressure. It's also used to treat oedema. According to IMS Health, Hygroton and its generics reported sales of approximately US$122 million MAT for 12-months ending September 2018 in the US market. 

Dr. Reddy’s is an integrated pharmaceutical company and through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – the company offers a portfolio of products and services including APls, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

On Wednesday, the shares of Dr. Reddy Laboratories opened at Rs. 2,590 per share as against Tuesday’s close of Rs. 2,590.20. After market hours, the shares closed at Rs. 2,570.40, down by 0.76 per cent or by 19.80 points. The intraday high was Rs 2,595.90 and intraday low was Rs. 2,549.20 per share on the BSE. Its 52-week high was Rs. 2,687.45 and 52-week low was Rs. 1,888 per share on the BSE. Meanwhile, the BSE Sensex closed at 35,716.95 level, up by 0.57 per cent.